Developmental disorders of academic skills in children: the efficacy and safety of Tenoten for children in the multicenter double-blind placebo-controlled randomized study

Zavadenko N.N.; Skripchenko N.V.; Gaynetdinova D.D.; Khaletskaya O.V.; Doronina O.B.; Suvorinova N.Yu.; Sagautdinova E.Sh.; Boychevskaya Yu.O.; Panteleeva M.V.; Teplyakova E.D.; Antonova T.I.

doi:https://doi.org/10.17116/jnevro202012009128

Zavadenko N.N.

Pirogov Russian National Research Medical University

ORCID: 0000-0003-0103-7422

Skripchenko N.V.

Children’s Research and Clinical Center for Infectious Diseases;
St. Petersburg State Pediatric Medical University

Gaynetdinova D.D.

Kazan State Medical University

Khaletskaya O.V.

Privolzhsky Research Medical University;
LLC «NIJMEDKLINIKA»

Doronina O.B.

Sibneiromed

ORCID: 0000-0002-5136-7430

Suvorinova N.Yu.

Pirogov Russian National Research Medical University

Sagautdinova E.Sh.

Sverdlovsk Region Children’s Clinical Hospital of Rehabilitation The Scientific and Practical Center Bonum

Boychevskaya Yu.O.

Specialized Clinical Psychiatric Hospital No. 1 of the Ministry of Health of the Krasnodar Region

Panteleeva M.V.

Moscow Regional Research and Clinical Institute («MONIKI»)

Teplyakova E.D.

«Children’s city polyclinic No. 4» of Rostov-on-Don

Antonova T.I.

St. Petersburg «Children’s city clinic No. 35»

Developmental disorders of academic skills in children: the efficacy and safety of Tenoten for children in the multicenter double-blind placebo-controlled randomized study

Authors:

Zavadenko N.N., Skripchenko N.V., Gaynetdinova D.D., Khaletskaya O.V., Doronina O.B., Suvorinova N.Yu., Sagautdinova E.Sh., Boychevskaya Yu.O., Panteleeva M.V., Teplyakova E.D., Antonova T.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(9): 28‑36

DOI: 10.17116/jnevro202012009128

Read: 13516 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zavadenko NN, Skripchenko NV, Gaynetdinova DD, et al. . Developmental disorders of academic skills in children: the efficacy and safety of Tenoten for children in the multicenter double-blind placebo-controlled randomized study. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(9):28‑36. (In Russ.)
https://doi.org/10.17116/jnevro202012009128

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Abstract:

OBJECTIVE

To evaluate the efficacy and safety of tenoten for children in the treatment of specific developmental disorders of academic skills in children of 1—3 grades.

MATERIAL AND METHODS

Two hundred and forty children, aged 7—9 years, (Total set, Safety population) with verified specific reading disorder (F81.0), specific spelling disorder (F81.1), specific disorder of arithmetical skills (F81.2), mixed disorder of scholastic skills (F81.3; F81.2+F81.0, or F81.2+F81.1, or F81.2+F81.0+F81.1), diagnosed with the use of logopedic or psychological testing (15—35 scores in Fotekova T.A. and Akhutina T.V. reading and writing tests; 5—15 scores in arithmetical subscale of the Wechsler Intelligence Scale for Children) were enrolled in the study. CT was conducted in 10 clinical centers in Russian Federation in 2015— 2019. Patients were randomized into two groups. The first one (n=122) received tenoten for children in a dose of 1 tablet 3 times a day, the second one (n=118) was administered placebo in the same dosage regimen. The clinical data on 237 children (121 of the tenoten group and 116 of the placebo group) were used for Intention-to-treat efficacy analysis. Data on 220 children (115 of the tenoten group and 105 of the placebo group) were included in Per-protocol analysis. The duration of study was 12 weeks. The mean total academic skills (reading, spelling, and counting) score in groups after 12 weeks of treatment was set as the primary efficacy endpoint.

RESULTS

The mean total academic skills score increased by 18.55±15.87 points. The significant total difference between the median changes in the total score in the tenoten and placebo groups was 5 points. There was a trend towards positive changes in reading and spelling mean scores in tests that didn’t reach statistical significance due to lack of normal distribution of points in samples. There were 73 adverse events (AEs) in 42 patients of the tenoten group and 95 AEs in 31 children of the placebo group. No serious or severe AEs were registered in the tenoten group. No AEs definitely related to the study treatment were registered. No negative drug interactions were observed in the tenoten group.

CONCLUSIONS

Tenoten for children is an effective and safe treatment for specific developmental disorders of academic skills in primary school children. Tenoten for children is well tolerated. The treatment is characterized by a high level of adherence of children and their parents to therapy.

Keywords:

specific developmental disorders of academic skills

tenoten for children

Authors:

Zavadenko N.N.

Pirogov Russian National Research Medical University

ORCID: 0000-0003-0103-7422

Skripchenko N.V.

Children’s Research and Clinical Center for Infectious Diseases;
St. Petersburg State Pediatric Medical University

Gaynetdinova D.D.

Kazan State Medical University

Khaletskaya O.V.

Privolzhsky Research Medical University;
LLC «NIJMEDKLINIKA»

Doronina O.B.

Sibneiromed

ORCID: 0000-0002-5136-7430

Suvorinova N.Yu.

Pirogov Russian National Research Medical University

Sagautdinova E.Sh.

Sverdlovsk Region Children’s Clinical Hospital of Rehabilitation The Scientific and Practical Center Bonum

Boychevskaya Yu.O.

Specialized Clinical Psychiatric Hospital No. 1 of the Ministry of Health of the Krasnodar Region

Panteleeva M.V.

Moscow Regional Research and Clinical Institute («MONIKI»)

Teplyakova E.D.

«Children’s city polyclinic No. 4» of Rostov-on-Don

Antonova T.I.

St. Petersburg «Children’s city clinic No. 35»

Received:

06.07.2020

Accepted:

30.07.2020

Close metadata

References:

Wenar Ch, Kerig P. Developmental Psychopathology: From Infancy Through Adolescence: trans. from English St. Petersburg: Prime Euroznak, 2007;670. (In Russ.).
Aleksandrovskij Y.A., Neznanov N.G. Psikhiatrija: nacional’noe rukovodstvo. 2 izd., pererab. i dop. M: GEOTAR-Media. 2020;1008. (In Russ.).
Wiznitzer M, Scheffel DL. Learning Disabilities. In: Ronald B. David, editor. Child and adolescent neurology: Blackwell’s neurology and psychiatry access series. 2nd ed. Oxford: Wiley-Blackwell, 2005;511-523.
Handler SM, Fierson WM. Section on Ophthalmology; Council on Children with Disabilities; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Learning disabilities, dyslexia, and vision. Pediatrics. 2011;127(3):e818-e856. https://doi.org/10.1542/peds.2010-3670
ICD-10 — The International Classification of Diseases. The Classification of Mental and Behavioral Disorders. Research and Diagnostic Criteria. St. Petersburg: WHO, 1994;208. (In Russ).
McDowell M. Specific learning disability. Journal of paediatrics and child health. 2018;54(10):1077-1083. https://doi.org/10.1111/jpc.14168
Zablotsky B, Black LI, Maenner MJ, Schieve LA, Danielson ML, Bitsko RH, Blumberg SJ, Kogan MD, Boyle CA. Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009-2017. Pediatrics. 2019;144(4):34-38. https://doi.org/10.1542/peds.2019-0811
Maklakov AG. Obshhaja psikhologija. SPb: Piter, 2008;583. (In Russ.).
Morsanyi K, van Bers BMCW, McCormack T, McGourty J. The prevalence of specific learning disorder in mathematics and comorbidity with other developmental disorders in primary school-age children. British journal of psychology. 2018;109(4):917‐940. https://doi.org/10.1111/bjop.12322
Swaiman KF. Nonverbal learning disabilities and associated disorders. In: Swaiman KF, Ashwal S, Ferriero DM, Schor NF, Finkel RS, Gropman AL, Pearl PL, Shevell M, eds. Swaiman’s Pediatric Neurology. 6th ed. Philadelphia: Elsevier, 2017;e1070-e1078
Fotekova TA, Akhutina TV. Diagnostika rechevyh narushenij shkol’nikov s ispol’zovaniem nejropsihologicheskih metodov: Posobie dlja logopedov i psikhologov. M.: ARKTI, 2002;136. (In Russ.).
Wechsler D. The Wechsler intelligence scale for children − fourth edition. London: Pearson Assessment, 2004.
Semenovich ML, Manelis NG, Khaustov AV, Kozorez AI, Morozova EV. Description of the Assessment of Basic Language and Learning Skills Revisited (ABLLS:R). Autizm i narušenie razvitiâ = Autism and Developmental Disorders. 2015;13(3):30-10. (In Russ.). https://doi.org/10.17759/autdd.2015130301
Sundberg ML. VB-MAPP Verbal Behavior Milestones Assessment and Placement Program: A Language and Social Skills Assessment Program for Children with Autism Or Other Developmental Disabilities: Guide. California: AVB Press, 2008;239.
National Institute of Child Health and Human Development. What are the treatments for learning disabilities? [Internet]. Data Access 20.05.2020 https://www.nichd.nih.gov/health/topics/learning/conditioninfo/treatment
Epstein O. The spatial homeostasis hypothesis. Symmetry. 2018;10(4):103. https://doi.org/10.3390/sym10040103
Epstein OI. Reliz-aktivnost’ (sovremennyj vzgljad na gomeopatiju i negomeopatiju). M.: Izdatel’stvo RAMN, 2017;48. (In Russ.).
Voronina TA, Molodavkin GM, Borodavkina MV, Kheyfets IA, Dugina YuL, Sergeeva SA. Nootropic and antiamnestic effects of Tenoten (pediatric formulation) in immature rat pups. Bulletin of Experimental Biology and Medicine. 2009;148. Suppl. 1:164-166. (In Russ.).
Meshcheryakov AF. Antidepressant properties of antibodies to serotonin, brain-specific S100 protein, and delta sleep-inducing peptide. Bulletin of Experimental Biology and Medicine. 2003; Supplement 1:23-25. (In Russ.).
Pankova TM, Starostina MV, Shtark MB, Epstein OI. Neuroprotective effect of ultra-low doses of antibodies against S100 protein in neuroblastoma culture during oxygen and glucose deprivation. Bulletin of Experimental Biology and Medicine. 2007;144(9):260-264. (In Russ.).
Khakimova GR, Voronina TA, Dugina YuL, Ertuzun IA, Epshtein OI. Farmacological effects of anti-S100 in release-active form and mechanisms of their realisation. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(4):100-113. (In Russ.). https://doi.org/10.17116/jnevro201611641100-113
Kheifets IA, Dugina YuL, Voronina TA, Molodavkin GM, Martyushev-Poklad AV, Sergeeva SA, Epstein OI. Involvement of the serotoninergic system in the mechanism of action of ultralow dose antibodies to S-100 protein. Bulletin of Experimental Biology and Medicine. 2007;143(5):535-537. (In Russ.).
Akarachkova ES, Blinov DV, Kotova OV, Travnikova EV, Tsareva EV. Stress and anxiety in children: causes and methods of correction. Pharmateca. 2018;1(354):28-35. (In Russ.).
Bovbel IE, Mukalova OA, Horlikova OA, Efimenko SE. Use of ultra-low doses of antibodies to brain-specific protein S-100 in effective therapy transient tics in children. Paediatrics. Eastern Europe. 2016;4(1):191-199. (In Russ.).
Keshishyan ES, Bykova OV, Borisova MN, Minaycheva LI, Chernaya NL, Panteleeva MV, Sagutdinova ESh, Perminova OA, Panina OS, Romanova TA, Gaynetdinova DD. Therapy of perinatal brain injury outcomes: results of a multicenter double-blind placebo-controlled randomized study of Tenoten for children (liquid dosage form). S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(7):33-39. (In Russ.). https://doi.org/10.17116/jnevro201911907233
Kovaleva AM, Polevichenko EV. Vozmozhnosti korrekcii rechevogo razvitija u detej s vkljucheniem v shemu lechenija preparata Tenoten. Glavnyj vrach. Nevrologija. 2010;1(20):28-29. (In Russ.).
Lobov MA, Borisova MN, Osipova OV, Panteleeva MV, Tarakanova TYu. Monotherapy by preparation Tenoten for children in cases of autonomic distension. Pediatria. Journal named after G.N. Speransky. 2008;87(5):107-109. (In Russ.).
Tarasova ON, Shalimov VF. Experience of Using Tenoten for Children in Therapy of Learning Disorders in Children. Effective Pharmacotherapy. 2015;1:4-12. (In Russ.).
Donato R. S-100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell. Biol. 2001;33:637-668. https://doi.org/10.1016/s1357-2725(01)00046-2
Hyden H, Cupello A, Palm A. Effect of anti-S-100 serum on 36Cl- ion permeability across the Deiters’ neuron plasma membrane. Cell Mol Neurobiol. 1987;7(4):439-445.
Zavadenko NN, Suvorinova NYu. Attention deficit hyperactivity disorder treatment with Tenoten for children: the results of results of double blind placebo controlled randomized trial. Effective pharmacotherapy. Neurology. 2010;19:42-47. (In Russ.).
Zavadenko NN, Simashkova NV, Vakula IN, Suvorinova NYu, Balakireva EE, Lobacheva MV. Current possibilities in pharmacotherapy of anxiety disorders in children and adolescents. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115(11):33-39. (In Russ.). https://doi.org/10.17116/jnevro201511511133-39
Kheyfets I, Chutko L, Surushkina S, Dugina J, Kachanova M, Sergeeva S, Epstein O. Clinical efficacy of Tenoten for children in treatment of attention deficit and hyperactivity disorder. European Psychiatry. 2010;25(1):429. https://doi.org/10.1016/S0924-9338(10)70425-9
Dyakonova EN, Shalimov VF. The efficacy of tenoten for children in the treatment of motor and speech disorders in children with perinatal damage of the central nervous system. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(4):17-30. (In Russ.). https://doi.org/10.17116/jnevro20161163217-30
Zavadenko NN, Roumyantseva MV. Dyslexia: underlying mechanisms and treatment principles. Russian journal of child neurology. 2008;3(1):3-9. (In Russ.).